ROLE OF BIOMARKERS IN EPILEPTOGENESIS: A CONCISE REVIEW

ATUL A. BARAVKAR; SAGAR D. SHINDE; NITIN B. AHER

doi:10.22159/ijpps.2022v14i1.43306

Authors

ATUL A. BARAVKAR Agricultural Development Trust’s Shardabai Pawar Institute of Pharmaceutical Sciences and Research, Baramati, India https://orcid.org/0000-0002-0469-9838
SAGAR D. SHINDE Agricultural Development Trust’s Shardabai Pawar Institute of Pharmaceutical Sciences and Research, Baramati, India https://orcid.org/0000-0003-0417-6014
NITIN B. AHER Ashvin College of Pharmacy, Sangmaner, India

DOI:

https://doi.org/10.22159/ijpps.2022v14i1.43306

Keywords:

Epilepsy, Biomarker, Seizures, Ictogenesis

Abstract

Epilepsy is a gathering of ongoing neurological problems described by intermittent, unconstrained, and unusual seizures. It is one of the most widely recognized neurological messes, influencing a huge number of individuals around the world. A biomarker is characterized as a dispassionately estimated normal for an ordinary or obsessive natural interaction. Recognizable proof and legitimate approval of biomarkers of epileptogenesis, the improvement of epilepsy, and ictogenesis, the affinity to create unconstrained seizures, may foresee the improvement of an epilepsy condition; recognize the presence and seriousness of tissue equipped for producing unconstrained seizures; measure movement after the condition is set up; furthermore, decide pharmacoresistant. Such biomarkers could be utilized to make creature models for more savvy screening of potential antiepileptogenic and antiseizure medications and gadgets and to lessen the expense of clinical preliminaries by enhancing the preliminary populace and going about as proxy markers to abbreviate the preliminary span. The destinations of the biomarker subgroup for the London Studio were to characterize approaches for distinguishing conceivable biomarkers for these reasons. Examination to recognize dependable biomarkers may likewise uncover basic instruments that could serve as helpful focuses for the improvement of new antiepileptogenic and antiseizure compounds.

Downloads

Download data is not yet available.

References

Stafstrom CE, Carmant L. Seizures and epilepsy: an overview for neuroscientists. Cold Spring Harb Perspect Med. 2015 Jul;5(6):(a022462). doi: 10.1101/Csh Perspect.a022426, PMID 26033084.

Jerome EJ, Pitkanen A, Loeb JA, Dudek EF, Bertram EH, Cole AJ, Moshe SL, Wiebe S, Fuerman BE, Jensen FE, Mody I, Nehlig A, Vezzani A. Epilepsy biomarkers. Epilepsia. 2013 Aug;54(4):61-9.

Bone I, Dein S. Religion, spirituality, and epilepsy. Epilepsy Behav. 2021 Sep;122:108219. doi: 10.1016/j.yebeh. 2021.108219, PMID 34343961.

Tufenkjian K, Lüders HO. Seizure semiology: its value and limitations in localizing the epileptogenic zone. J Clin Neurol. 2012 Dec;8(4):243-50. doi: 10.3988/jcn.2012.8.4.243, PMID 23323131.

Sechidis K, Papangelou K, Metcalfe PD, Svensson D, Weatherall J, Brown G. Distinguishing prognostic and predictive biomarkers: an information-theoretic approach. Bioinformatics. 2018 Oct;34(19):3365-76. doi: 10.1093/ bioinformatics/ bty357, PMID 29726967.

Engel J, Pitkänen A. Biomarkers for epileptogenesis and its treatment. Neuropharmacology. 2020;167:107735. doi: 10.1016/j.neuropharm.2019.107735. PMID 31377200.

Samprathi M, Jayashree M. Biomarkers in COVID-19: an up-to-date review. Front Pediatr. 2021 Mar;8:1-12. doi: 10.3389/fped.2020.607647, PMID 607647.

Goldenberg MM. Overview of drugs used for epilepsy and seizures: etiology, diagnosis, and treatment. P T. 2010 Jul;35(7):392-415. PMID 20689626.

Kirmani BF, Au K, Mir S, Hogan M, Kim D, Sharma P. Biomarkers for epileptogenesis in patients with autoimmune epilepsy. NN; 2020. doi: 10.20517/2347-8659.2020.29.

Vespa PM, McArthur DL, Xu Y, Eliseo M, Etchepare M, Dinov I, Alger J, Glenn TP, Hovda D. Nonconvulsive seizures after traumatic brain injury are associated with hippocampal atrophy. Neurology. 2010 Aug;75(9):792-8. doi: 10.1212/WNL.0b013e3181f07334, PMID 20805525.

Pitkanen A, Loscher W, Vezzani A, Becker AJ, Simonato M, Lukasiuk K, Grohn O, Bankstahl JP, Friedman A, Aronica E, Gorter JA, Ravizza T, Sisodiya SM, Kokaia M, Beck H. Advances in the development of biomarkers for epilepsy. Lancet Neurol. 2016 Jul;15(8):843-56. doi: 10.1016/S1474-4422(16)00112-5, PMID 27302363.

Nagarathnam M, Vengamma B, Shalini B, Latheef SAA. Stigma and polytherapy: predictors of quality of life in patients with epilepsy from south India. Ann Indian Acad Neurol. 2017 Sep;20(3):233-41. doi: 10.4103/aian.AIAN_36_17, PMID 28904455.

Quigg M, Smithson SD, Fowler KM, Sursal T, Herzog AG, NIH Progesterone Trial Study Group. Laterality and location influence catamenial seizure expression in women with partial epilepsy. Neurology. 2009 Jul;73(3):223-7. doi: 10.1212/WNL.0b013e3181ae7adf, PMID 19620611.

Yu JY, Pearl PL. Metabolic causes of epileptic encephalopathy. Epilepsy Res Treat. 2013 May;2013:124934. doi: 10.1155/2013/124934.

Mead MN. Benefits of sunlight: a bright spot for human health. Environ Health Perspect. 2008 Apr;116(4):A160-7. doi: 10.1289/ehp.116-a160, PMID 18414615.

Alkhidze M, Lomidze G, Kasradze S, Tsiskaridze A. Characteristics and predictive biomarkers of drug-resistant epilepsy- study in Georgia. NN. 2017 Sep;4(9):191-8. doi: 10.20517/2347-8659.2017.14.

Petrillo S, Pietrafusa N, Trivisano M, Calabrese C, Saura F, Gallo MG, Bertini ES, Vigevano F, Specchio N, Piemonte F. Imbalance of systemic redox biomarkers in children with epilepsy: role of ferroptosis. Antioxidants (Basel). 2021 Aug;10(8):1-13. doi: 10.3390/antiox10081267, PMID 34439515.

Pitkanen A, Ekolle Ndode Ekane X, Lapinlampi N, Puhakka N. Epilepsy biomarkers- Toward etiology and pathology specificity. Neurobiol Dis. 2019 Mar;123:42-58. doi: 10.1016/j.nbd.2018.05.007, PMID 29782966.

Budikayanti A, Chaliana C, Louisa M, Setiabudy R. Development and validation of carbamazepine plasma concentrations measurement and its application on epilepsy patients. Int J Pharm Pharm Sci. 2017 Jul;9(9):1-5.

Jerome EJ. Approaches to refractory epilepsy. Ann Indian Acad Neurol. 2014 Mar;17;Suppl 1:S12-17.

Lukasiuk K, Becker AJ. Molecular biomarkers of epileptogenesis. Neurotherapeutics. 2014 Apr;11(2):319-23. doi: 10.1007/s13311-014-0261-6, PMID 24566938.

Niemantsverdriet E, Valckx S, Bjerke M, Engelborghs S. Alzheimer’s disease CSF biomarkers: clinical indications and rational use. Acta Neurol Belg. 2017 Jul;117(3):591-602. doi: 10.1007/s13760-017-0816-5, PMID 28752420.

Shimizu S, Hirose D, Hatanaka H, Takenoshita N, Kaneko Y, Ogawa Y, Sakurai H, Hanyu H. Role of neuroimaging as a biomarker for neurogenerative diseases. Front Neurol. 2018 Apr;9(265):1-6.

Glaba P, Latka M, Krause MJ, Kuryto M, Jernajczyk W, Walas W, West BJ. Changes in interictal pretreatment and post-treatment EEG in childhood absence epilepsy. Front Neurosci. 2020 Mar;14(196):1-9.

Cole JH, Marioni RE, Harris SE, Deary IJ. Brain age and other bodily ’ages’: implications for neuropsychiatry. Mol Psychiatry. 2019 Jun;24(2):266-81. doi: 10.1038/s41380-018-0098-1, PMID 29892055.

Höller Y, Nardone R. Quantitative EEG biomarkers for epilepsy and their relation to chemical biomarkers. Adv Clin Chem. 2021 Nov;102:271-336. doi: 10.1016/bs.acc.2020.08.004, PMID 34044912.

Baraban SC. Emerging epilepsy models: insights from mice, flies, worms and fish. Curr Opin Neurol. 2007 Apr;20(2):164-8. doi: 10.1097/WCO.0b013e328042bae0, PMID 17351486.

Chen X, Chen H, Dai M, Ai J, Li Y, Mahon B, Dai S, Deng Y. Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions. Oncotarget. 2016 Jun;7(24):36622-31. doi: 10.18632/oncotarget.9124, PMID 27153558.

Simonato M, Agoston DV, Brooks Kayal A, Dulla C, Fureman B, Henshall DC, Pitkänen A, Theodore WH, Twyman RE, Kobeissy FH, Wang KK, Whittemore V, Wilcox KS. Identification of clinically relevant biomarkers of epileptogenesis- a strategic roadmap. Nat Rev Neurol. 2021 Feb;17(4):231-42. doi: 10.1038/s41582-021-00461-4, PMID 33594276.

Hirshi AP, Sethuraman M. Cerebrospinal fluid (CSF) analysis and interpretation in neurocritical care for acute neurological conditions. Indian Crit. Med. 2019 Jun;23;Suppl 2:S115-9.

Hayward KS, Schmidt J, Lohse KR, Peters S, Bernhardt J, Lannin NA, Boyd LA. Are we armed with the right data? Pooled individual data review of biomarkers in people with severe upper limb impairment after stroke. NeuroImage Clin. 2017 Sep;13:310-9. doi: 10.1016/j.nicl.2016.09.015, PMID 28053857.

Fish DR, Spencer SS. Clinical correlations: MRI and EEG. Magn reson imaging. 1995 Jan;13(8):1113-7. doi: 10.1016/0730-725x(95)02020-t, PMID 8750324.

Atik A, Stewart T, Zhang J. Alpha-synuclein as a biomarker for Parkinson’s disease. Brain Pathol. 2016 May;26(3):410-8. doi: 10.1111/bpa.12370, PMID 26940058.

Kanner AM, Mazarati A, Koepp M. Biomarkers of epileptogenesis: psychiatric comorbidities (?). Neurotherapeutics. 2014 Apr;11(2):358-72. doi: 10.1007/s13311-014-0271-4, PMID 24719199.

Forrester SN, Zmora R, Schreiner PJ, Jacobs DR, Roger VL, Thorpe RJ, Kiefe CI. Accelerated aging: a marker for social factors resulting in cardiovascular events? SSM Popul Health. 2021;13:100733. doi: 10.1016/j.ssmph.2021.100733. PMID 33532540.

Sojeetra N, Acharya R, Harisha Cr, Srivastava S, Misra A, Hegde S. Enetic barcoding and botanical studies on Pothos scandens L. leaves-an extra-pharmacopoeial drug of Ayurveda. Int J Pharm Pharm Sci. 2021 Jun;13(8):1-9.

Li C, Ashlock JC, Wang X. Quantifying repeatability reproducibility sources of error and capacity of a measurement: demonstrated using laboratory soil plasticity tests. Adv Civ Eng. 2019 Jul;2019:1-11. doi: 10.1155/2019/4539549, PMID 4539549.

ROLE OF BIOMARKERS IN EPILEPTOGENESIS: A CONCISE REVIEW

Authors

DOI:

Keywords:

Abstract

Downloads

References

Published

How to Cite

Issue

Section